The success of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) in preventing migraine and episodic cluster headaches in adults, coupled with minimal adverse events, has generated interest [4,5,6,7,8,9,10,11,12,13]. This evidence concerns the gene CALCA and migraine disorder.